IASLC 2024 World Conference on Lung Cancer: Dr. Singhi Discusses Highly Anticipated Sessions

Eric Singhi, MD, a thoracic medical oncologist at the University of Texas MD Anderson Cancer Center, shares what he’s looking forward to at the upcoming IASLC 2024 World Conference on Lung Cancer, which will be held September 7-10, in San Diego, California.

“I’m really excited to hear about some updates for our patients with early-stage resectable non-small cell lung cancer [NSCLC],” Dr. Singhi said.

He spoke about 2 key presentations on early-stage resectable NSCLC that will take place during the first Presidential Symposium, which will begin at 8:30 am PDT on Sunday, September 8.

“As you know, there have been a lot of advancements over the last few years in the space for our patients, especially with the introduction of immune checkpoint blockade in this setting, and we’re going to hear 2 really nice presentations,” Dr. Singhi said. “The first is perioperative versus neoadjuvant nivolumab for patients with resectable [NSCLC], and there’s going to be a patient-level data analysis of the CheckMate 77T study versus CheckMate 816.”

Patrick Forde, MBBCh, will present the patient-level data analysis, which will address a pressing issue in the field.

“The question that a lot of us have faced in clinic is when we’re choose choosing between adjuvant therapy, choosing between neoadjuvant therapy, and then, of course, perioperative therapy, how do we choose?” Dr. Singhi said. “I’m really looking forward to this patient-level data analysis of perioperative versus neoadjuvant immune checkpoint blockade in resectable [NSCLC] to aid us in how we make that decision.”

Dr. Singhi said that NeoCOAST-2, to be presented by Tina Cascone, MD, is another significant presentation to watch during the IASLC 2024 World Conference on Lung Cancer presidential sessions.

“The question that this is really asking is moving beyond our conventional PD1 inhibitors in this space for patients with early-stage resectable disease: Can we safely and efficaciously introduce novel immunotherapy molecules? It will be really exciting to see what’s happening in this landscape for our patients,” he said.

There will also be critical data in the metastatic setting, with Caicun Zhou, MD, PhD, presenting the primary analysis of HARMONi-2 at the meeting.

“We’ve already heard with the press release that ivonescimab shows significant progression-free survival improvement across all subgroups … I’m really looking forward to breaking down the data,” Dr. Singhi said. “We’ve heard that this is really the first drug to show a clinically meaningful benefit over pembrolizumab in a phase 3 setting for metastatic [NSCLC].”

Beyond these sessions, there are several other key updates that will be featured during the Presidential Symposia.

“What I’m really excited to hear about too from the Presidential Symposium is updates for patients who have HER2-positive metastatic [NSCLC]r and what’s going on in the HER2 therapy space for these patients,” Dr. Singhi said.

There are multiple updates in terms of HER2-directed therapy in lung cancer that will be presented during the second Presidential Symposium, which will take place at 8:30 am PDT on Monday, September 9.

“We’re going to hear about updates from the phase 1/2 SOHO-01 study, which is looking at the safety and efficacy of BAY 2927088 in patients with HER2-mutant [NSCLC],” Dr. Singhi said. “We’ll also hear about the Beamion LUNG-1 study, which is a phase 1B trial of zongertinib in patients who are very similar to the patients who were in the other study who have HER2-mutant–positive [NSCLC].”